insiderdelta
CoverageForm 410-K10-Q8-K13D13G13F

TELO · Telomir Pharmaceuticals, Inc. - Financials

Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.

Price · TELO

1YMax
Sign in to download
AnnualQuarterly

Income Statement

Line itemQ1 '26Q4 '25Q3 '25Q2 '25Q1 '25Q4 '24Q3 '24Q2 '24Q1 '24Q4 '23
Revenue----------
Cost of Revenue----------
Gross Profit----------
R&D$467.8K-$759.5K$42.8K$337.0K-$627.4K$667.6K$804.0K-
SG&A$573.5K-$387.0K$5.03M$1.85M-$5.38M$879.7K$741.5K-
Total Operating Expenses$1.04M-$1.15M$5.07M$2.19M-$6.01M$1.43M$1.92M-
D&A----------
Operating Income----$1.92M-----
Interest Expense$46--$1.3K--$757.2K$124.1K$4.34M-
Income Tax----------
Net Income($990.9K)-($1.10M)($5.07M)($2.18M)-($5.99M)($1.45M)($9.33M)-
EPS - Basic($0.03)-($0.03)$0.17($0.07)-($0.20)($0.06)($0.23)-
EPS - Diluted($0.03)-($0.03)$0.17($0.07)-($0.06)($0.05)($0.23)-

Balance Sheet

Line itemQ1 '26Q4 '25Q3 '25Q2 '25Q1 '25Q4 '24Q3 '24Q2 '24Q1 '24Q4 '23
Cash & Equivalents$5.56M$7.29M$7.33M$754.3K$403.0K$1.27M$834.6K$1.88M$3.27M$1.2K
Accounts Receivable----------
Inventory----------
Accounts Payable----------
Current Assets$5.79M$7.34M$7.40M$829.6K$491.2K$1.32M$1.04M$2.10M$3.50M$435.2K
Total Assets$5.79M$7.34M$7.40M$829.6K$491.2K$1.32M$1.04M$2.10M$3.50M$4.77M
Current Liabilities$827.3K$1.43M$422.8K$348.4K$652.3K$681.0K$599.9K$534.2K$486.6K$1.34M
Long-term Debt----------
Total Liabilities$827.3K$1.43M$422.8K$348.4K$652.3K$681.0K$599.9K$534.2K$486.6K$1.34M
Stockholders' Equity$4.96M$5.91M$6.98M$481.2K($161.1K)$643.0K$442.1K$1.57M($510.2K)$3.44M
Retained Earnings($42.00M)($41.01M)($38.95M)($37.85M)($32.78M)($30.60M)($27.70M)($21.77M)($20.32M)($14.06M)

Cash Flow

Line itemQ1 '26Q4 '25Q3 '25Q2 '25Q1 '25Q4 '24Q3 '24Q2 '24Q1 '24Q4 '23
Operating Cash Flow($1.77M)---($863.1K)---($1.94M)-
Investing Cash Flow----------
Financing Cash Flow$47.4K-------$5.21M-
CapEx----------
Free Cash Flow----------

Ratios

MetricQ1 '26Q4 '25Q3 '25Q2 '25Q1 '25Q4 '24Q3 '24Q2 '24Q1 '24Q4 '23
Profitability
Gross margin----------
Operating margin----------
EBITDA margin----------
Net margin----------
Free cash flow margin----------
FCF / Net income----------
R&D / Revenue----------
SG&A / Revenue----------
Effective tax rate----------
Return on assets-17.1%--14.9%-611.1%-443.8%--574.9%-68.9%-266.3%-
Return on equity-20.0%--15.8%-1053.5%1353.0%--1355.1%-92.4%1828.1%-
Return on invested capital----------
Liquidity
Current ratio7.005.1417.512.380.751.941.743.937.200.33
Quick ratio7.005.1417.512.380.751.941.743.937.200.33
Cash ratio6.725.1017.332.170.621.861.393.536.730.00
Leverage
Debt / Equity----------
Debt / Assets----------
Debt / EBITDA----------
Interest coverage----------
Equity multiplier1.171.241.061.72-3.052.062.361.34-6.871.39
Liabilities / Assets0.140.190.060.421.330.510.580.250.140.28
Efficiency
Asset turnover----------
Inventory turnover----------
Days sales outstanding----------
Days inventory outstanding----------
Days payable outstanding----------
Cash conversion cycle----------
Valuation
P / E---7.4x------
P / B9.0x-6.5x78.0x--430.0x83.1x--
P / S----------
EV / EBITDA----------
Growth
Revenue growth (YoY)----------
Revenue CAGR (3y)----------
Revenue CAGR (5y)----------
Gross profit growth (YoY)----------
Operating income growth (YoY)----------
Net income growth (YoY)54.5%-81.6%-249.9%76.6%-----
EPS growth (YoY)57.1%-50.0%-69.6%-----
EPS CAGR (3y)----------
EPS CAGR (5y)----------
FCF growth (YoY)----------
FCF CAGR (5y)----------
Book value growth (YoY)-819.6%1478.8%-69.3%68.4%-81.3%----

Peer comparison

Same SIC group: Pharmaceutical Preparations

CompanyRevenue (last FY)Net marginROE
LLY$65.18B31.7%77.8%
UTHR$3.18B41.9%18.8%
PFE$62.58B12.4%9.0%
ZTS$9.47B28.2%80.2%
VRTX$12.00B32.9%21.2%

Comparing Telomir Pharmaceuticals against the 5 most active filers in the same SIC group.